The previously reported SECA study demonstrated a dramatic 5-year survival improvement in patients with unresectable colorectal liver metastases (CLM) treated with liver transplantation (LT) compared with chemotherapy. The objective of this study was to assess whether immunosuppressive therapy accelerates the growth of pulmonary metastases in patients transplanted for unresectable CLM.
Introduction
About 50 per cent of patients with colorectal cancer (CRC) will develop metastases. The liver is the most frequent organ of relapse, followed by the lungs. Only 20 per cent of patients with metastatic disease are candidates for liver resection. Liver transplantation (LT) is standard treatment in patients with end-stage liver failure, and is currently also offered to selected patients with primary liver cancers such as hepatocellular carcinoma, hilar cholangiocarcinoma and liver metastases from neuroendocrine tumours 1 -6 . LT for malignant tumours comprises 16 per cent of all liver transplants in the European Liver Transplant Registry 7 . Organ transplantation requires lifelong immunosuppression, which may increase the risk of de novo malignancy 8 .
In the SECA (secondary cancer) study, 5-year survival was improved in patients with unresectable colorectal liver metastases (CLM) treated with LT compared with chemotherapy alone, with a 5-year overall survival (OS) rate of 56 versus 9 per cent respectively 9 . The majority of patients with CRC who underwent LT had a relapse, in the lung in two-thirds of cases 10 . Patients with pulmonary first-site recurrence had a 5-year survival rate of 72 per cent 10 . In patients with CRC who had a liver transplant the 5-year OS rate after relapse was 53 per cent 10, 11 . This contrasts with patients starting first-line chemotherapy, of whom about 5 per cent were alive at 5 years owing to progressive disease. The present study assessed whether immunosuppressive therapy accelerated the growth of pulmonary metastases in patients following LT.
Methods
The study group consisted of 11 patients from the SECA study who had a total of 18 pulmonary metastases resected after LT for unresectable CLM. At time of resection, these patients had only pulmonary metastases. They received immunosuppressive treatment according to the study protocol, which comprised induction with basiliximab (an interleukin-2 receptor antibody) and subsequent maintenance with an immunosuppressive regimen containing sirolimus (a mammalian target of rapamycin (mTOR) inhibitor), mycophenolate mofetil (an inosin monophosphate dehydrogenase inhibitor) and corticosteroids. Corticosteroid treatment was tapered to zero over the course of the first 6-12 months after surgery 11 . All patients from the SECA study also received acetylsalicylic acid (aspirin) to prevent thrombosis in the hepatic artery following LT. The control group was from a prospectively registered institutional rectal cancer database and consisted of 12 patients with locally advanced rectal cancer without metastases at the time of diagnosis/primary surgical treatment. They all received chemoradiotherapy of 2 Gy × 25, with concurrent capecitabine (825 mg/m 2 twice daily) during 5 weeks of radiotherapy. After surgery for the rectal tumour, all patients in the control group developed only pulmonary metastases. No patient in the SECA group or the control group was treated with chemotherapy between LT/pelvic surgery and the detection of pulmonary metastases, or between detection of pulmonary metastases and pulmonary resection.
Institutional review board and national regional ethics committee (S-05409) approval was obtained for the project. The SECA study was registered at ClinicalTrials .gov (NCT01311453). 
Chest CT review
CT was performed on different scanners as part of follow-up, either at the transplantation centre or at local hospitals. According to the study protocol, the SECA group had undergone CT of the thorax every 3 months in the first year, every 6 months in the second year, and once a year in years 3-10 after transplantation. Patients in the control group were followed at the same intervals until 5 years after surgery for metastases. Thickness of slices was 2⋅5-3⋅0 mm in both groups. All CT scans were imported into a Siemens syngo.via workstation (version VB10A; Siemens, Erlangen, Germany) and reviewed retrospectively by two radiologists. The largest diameter (Response Evaluation Criteria in Solid Tumours, RECIST) and tumour volumes were obtained by using a built-in semiautomated function. The measurements were manually controlled and adjusted if needed. Tumour volume doubling time (DT), based on diameter and tumour volume for individual metastases, was calculated using the Schwartz equation 12 : 
Statistical analysis
Statistical analyses were performed with SPSS ® version 24 (IBM, Armonk, New York, USA). DTs in SECA and control groups were visualized by a box plot. Several patients had more than one metastasis. Analyses were performed by considering the metastases as independent parameters. Groups of data were compared using the non-parametric Mann-Whitney U test and Spearman rank correlation coefficient. Survival data were estimated by means of the Kaplan-Meier method and compared with the log rank test. P < 0⋅050 was considered statistically significant.
Results
Patient and baseline characteristics are summarized in Table 1 . Median age at first pulmonary resection was 56 (range 45-67) years in the 11 patients in the SECA group and 63 (51-76) years in the 12 control patients (P = 0⋅069). Median sirolimus dose was 4 (range 2-5) mg/day, and median sirolimus serum concentration was 11⋅8 (range 6⋅0-16⋅5) μg/l before the first pulmonary resection. In the SECA group, the dose of aspirin was 75 mg/day after LT, except in one patient who received 160 mg daily. Median and control groups was 17 (6-42) and 18 (2-57) months respectively (P = 0⋅532). DFS rates at 1, 3 and 5 years were 64, 18 and 0 per cent after LT, compared with 75, 25 and 0 per cent after pelvic surgery in the control group (Fig. 1) .
CT intervals and tumour size
There was no time difference from final CT to resection of pulmonary metastases between the two groups ( Table 2) . Median metastatic tumour diameter at detection was larger in the control group, but similar at pulmonary resection; the increase in tumour diameter (RECIST) with time for individual metastases is shown in Fig. 2 . Median tumour volume at detection was smaller in the SECA group, but similar at the time of pulmonary resection ( Table 2) ; the increase in tumour volume with time for individual metastases is shown in Fig. 3 . At histological examination, the median (range) diameter of resected pulmonary metastases was 15 (5-23) mm in the SECA group and 15 (8-30) mm in the control group (P = 0⋅503). Tumour volume at the last CT before pulmonary resection (V last CT ) was correlated with the diameter observed at histological examination after resection (correlation coefficient 0⋅78, P < 0⋅001).
Tumour doubling times
The median (range) DT by diameter was 125 (27-430) days in the SECA group and 110 (30-320) days in the control group (P = 0⋅658). DT of the metastases by volume was also similar (Fig. 4) .
CT characteristics and distribution
Metastases in both groups were distributed to all lung lobes and were mostly peripheral. In the SECA group, 17 of the 18 metastases were well defined compared with 21 of 26 in the control group. CT characteristics and the distribution of the pulmonary metastases in the two groups are summarized in Table 2 .
Recurrence and survival after resection of pulmonary metastases
Eight patients in the SECA group had a single pulmonary resection, two patients had two separate resections, and one patient has undergone resection seven times and is alive with no evidence of disease almost 10 years after LT and 8 years after the first pulmonary resection. Four of the patients developed extrapulmonary relapse. Estimated 5-year DFS and OS rate from first pulmonary resection in the SECA group was 39 and 51 per cent respectively. In the control group, eight patients had one, three patients had two, and one patient had three pulmonary resections. In addition to the four patients who relapsed with resectable pulmonary metastases, three patients had a relapse after the first pulmonary resection. One patient developed multiple pulmonary metastases, another had a pulmonary relapse and received stereotactic radiotherapy, and one patient developed a rhabdomyosarcoma.
There was no difference between the two groups in DFS (P = 0⋅478) or OS (P = 0⋅084) after first pulmonary resection. The numbers at risk are too small to present in a meaningful Kaplan-Meier curve.
Discussion
These results suggest that immunosuppression after LT for unresectable CLM does not accelerate growth of pulmonary metastases. De novo cancers as well as cancer recurrence may be promoted by immunosuppression owing to various mechanisms, including decreased immunosurveillance 8, 13, 14 , facilitated action of oncogenic viruses 15 and direct alteration of DNA 16 . A meta-analysis 17 reported that pretransplant malignancy was associated with an increased risk of all-cause and cancer-specific mortality, and of developing de novo malignancies after transplantation compared with rates in patients without pretransplant malignancy.
It has been suggested that de novo malignancy after transplantation is diagnosed at younger age than in the general population and may behave more aggressively 18 -21 . Despite the heavy immunosuppressive drug combinations used in the SECA study, increased growth rates of the pulmonary metastases were not observed. There was no relation between plasma sirolimus concentration and DFS or growth rates of pulmonary metastases in the SECA group (data not shown). The immunosuppressive regimen used in the SECA study contained mycophenolate mofetil, which has been reported 22 to reduce the risk of CRC development compared with ciclosporin-azathioprine immunosuppression. mTOR inhibitors have shown antiproliferative properties 23 , with increased response and OS rates in patients with breast cancer and kidney cancer 24, 25 .
According to the SECA study protocol, all patients received aspirin to prevent arterial thrombosis. A recent Norwegian study 26 of 23 162 patients showed that aspirin use after diagnosis of CRC was independently associated with improved CRC-specific survival and OS. The protocol-specified aspirin use may inhibit the growth of pulmonary metastases, but this is not yet known.
The present study has some limitations, including its retrospective design and the fact that different CT scanners and scan protocols were used. However, two dedicated radiologists reassessed all metastases to achieve consensus, and CT-determined volume correlated with histological findings. The number of metastases included in the study was small. Only patients with resectable pulmonary metastases that were confirmed histologically as CRC metastases were included in this study. In general, it is difficult to find an ideal control group to compare with liver-transplanted patients. Patients in the control group had a lower tumour burden at the time of pelvic surgery compared with the tumour burden at LT in the SECA group, and had received less chemotherapy. It is likely that the control group had a more favourable tumour biology compared with that of the transplanted group, yet immunosuppression did not adversely impact tumour progression in the transplanted group. The size of the pulmonary metastases at detection was larger in the control group, but similar at the time of pulmonary resection. It is conceivable that this represented a selection bias, whereby DTs were faster in the control group, artificially improving times in the SECA group. This does not detract from the simple message that LT is possible for CLM, with no discernable negative influence on disease activity, on the basis of this small, retrospective, lung-focused study.
